Red blood cells treated with the amustaline (S-303) pathogen reduction system: a transfusion study in cardiac surgery

Transfusion

Volumn 58, Issue 4, 2018, Pages 905-916

  Brixner, Veronika ^a   Kiessling, Arndt Holger ^b   Madlener, Katharina ^c   Müller, Markus M ^a   Leibacher, Johannes ^a   Dombos, Sarah ^a   Weber, Iuliia ^a   Pfeiffer, Hans Ulrich ^a   Geisen, Christof ^a   Schmidt, Michael ^a   Henschler, Reinhard ^d,e   North, Anne ^f   Huang, Norman ^f   Mufti, Nina ^f   Erickson, Anna ^f   Ernst, Christine ^f   Rico, Salvador ^f   Benjamin, Richard J ^f   Corash, Laurence M ^f   Seifried, Erhard ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c KERCKHOFF HEART CENTER   (Germany)

^d Blood Center Zürich   (Switzerland)

^e Red Cross Blood Service Graubünden   (Switzerland)

^f CERUS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMUSTALINE; HEMOGLOBIN; (N,N-BIS(2-CHLOROETHYL))-2-AMINOETHYL-3-((ACRIDIN-9-YL)AMINO)PROPIONATE; ACRIDINE DERIVATIVE; CHLORMETHINE DERIVATIVE; GLUTATHIONE;

AGED; ARTICLE; CARDIOPULMONARY FUNCTION; CARDIOVASCULAR SURGERY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ERYTHROCYTE TRANSFUSION; FEMALE; HEART SURGERY; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; KIDNEY FAILURE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; SIX MINUTE WALK TEST; ACUTE KIDNEY FAILURE; BACTEREMIA; BLOOD SAFETY; BLOOD TRANSFUSION REACTION; BLOODBORNE BACTERIUM; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; ERYTHROCYTE; GRAFT VERSUS HOST REACTION; HEART FUNCTION TEST; POSTOPERATIVE COMPLICATION; PROCEDURES; TRANSMISSION; VERY ELDERLY; VIREMIA; VIRUS INACTIVATION;

ACRIDINES; ACUTE KIDNEY INJURY; AGED; AGED, 80 AND OVER; BACTEREMIA; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; CARDIAC SURGICAL PROCEDURES; DOUBLE-BLIND METHOD; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FEMALE; GLUTATHIONE; GRAFT VS HOST DISEASE; HEART FUNCTION TESTS; HEMOGLOBINS; HUMANS; LIVER FAILURE; MALE; NITROGEN MUSTARD COMPOUNDS; POSTOPERATIVE COMPLICATIONS; TRANSFUSION REACTION; VIREMIA; VIRUS INACTIVATION;

EID: 85042607509     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14528     Document Type: Article

References (48)

1. Tilak R, Ray S, Tilak VW, et al. Dengue, chikungunya … and the missing entity—Zika fever: a new emerging threat. Med J Armed Forces India 2016;72:157-63.
2. Lanteri MC, Kleinman SH, Glynn SA, et al. Zika virus: a new threat to the safety of the blood supply with worldwide impact and implications. Transfusion 2016;56:1907-14.
3. Stramer SL, Dodd RY. Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress. Transfusion 2013;53:2375-83.
4. Moritz ED, Winton CS, Tonnetti L, et al. Screening for Babesia microti in the U.S. blood supply. N Engl J Med 2016;375:2236-45.
5. Lustig Y, Mendelson E, Paran N, et al. Detection of Zika virus RNA in whole blood of imported Zika virus disease cases up to 2 months after symptom onset, Israel, December 2015 to April 2016. Euro Surveill 2016;21(26).
6. Kleinman S, Stassinopoulos A. Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation. Transfusion 2015;55:2983-3000.
7. Kleinman S, Cameron C, Custer B, et al. Modeling the risk of an emerging pathogen entering the Canadian blood supply. Transfusion 2010;50:2592-606.
8. Walther-Wenke G, Schrezenmeier H, Deitenbeck R, et al. Screening of platelet concentrates for bacterial contamination: spectrum of bacteria detected, proportion of transfused units, and clinical follow-up. Ann Hematol 2010;89:83-91.
9. Corash L. Bacterial contamination of platelet components: potential solutions to prevent transfusion-related sepsis. Expert Rev Hematol 2011;4:509-25.
10. Kopolovic I, Ostro J, Tsubota H, et al. A systematic review of transfusion-associated graft-versus-host disease. Blood 2015;126:406-14.
11. Salunkhe V, van der Meer PF, de Korte D, et al. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apher Sci 2015;52:19-34.
12. Seltsam A, Müller TH. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013;162:442-54.
13. Henschler R, Seifried E, Mufti N. Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother 2011;38:33-42.
14. Conlan MG, Vichinsky E, Snyder E, et al. S-303 pathogen inactivated red blood cells in patients with hemoglobinopathies participating in chronic transfusion programs: preliminary safety and efficacy results. Vox Sang 2005;89:121.
15. Benjamin RJ, McCullough J, Mintz PD, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion 2005;45:1739-49.
16. Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 2014;41:309-25.
17. Laughhunn A, Santa Maria F, Broult J, et al. Amustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell components. Transfusion 2017;57:779-89.
18. Cancelas JA, Dumont LJ, Rugg N, et al. Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. Transfusion 2011;51:2367-76.
19. Cancelas JA, Gottschall JL, Rugg N, et al. Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study. Vox Sang 2017;112:210-8.
20. Heim MU, Hellstern P. [New cross-sectional guidelines of the German Medical Association for hemotherapy with fresh frozen plasma. Evidence-based recommendations for risk-benefit assessment]. Anaesthesist 2010;59:80-5.
21. Bundesärztekammer. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie) [Guidelines for the collection of blood and blood components and for the use of blood products]. Berlin: German Medical Association; 2010 [cited 2018 Jan 11]. Available from: http://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/RiliHaemotherapie2010.pdf.
22. Alghamdi AA, Davis A, Brister S, et al. Development and validation of Transfusion Risk Understanding Scoring Tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needs. Transfusion 2006;46:1120-9.
23. Oliveira GU, Oliveira Carvalho V, de Assis Cacau LP, et al. Determinants of distance walked during the six-minute walk test in patients undergoing cardiac surgery at hospital discharge. J Cardiothorac Surg 2014;9:95.
24. North A, Ciaravino V, Mufti N, et al. Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment. Transfusion 2011;51:2208-18.
25. Arora P, Kolli H, Nainani N, et al. Preventable risk factors for acute kidney injury in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2012;26:687-97.
26. Lagny MG, Jouret F, Koch JN, et al. Incidence and outcomes of acute kidney injury after cardiac surgery using either criteria of the RIFLE classification. BMC Nephrol 2015;16:76.
27. Corredor C, Thomson R, Al-Subaie N. Long-term consequences of acute kidney injury after cardiac surgery: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 2016;30:69-75.
28. Zhou J, Liu Y, Tang Y, et al. A comparison of RIFLE, AKIN, KDIGO, and Cys-C criteria for the definition of acute kidney injury in critically ill patients. Int Urol Nephrol 2016;48:125-32.
29. Haase M, Bellomo R, Matalanis G, et al. A comparison of the RIFLE and Acute Kidney Injury Network classifications for cardiac surgery-associated acute kidney injury: a prospective cohort study. J Thorac Cardiovasc Surg 2009;138:1370-6.
30. Hobson CE, Yavas S, Segal MS, et al. Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. Circulation 2009;119:2444-53.
31. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int 2008;73:538-46.
32. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2:1–138 [cited 2018 Feb 16]. Available from: http://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf.
33. Gayda M, Temfemo A, Choquet D, et al. Cardiorespiratory requirements and reproducibility of the six-minute walk test in elderly patients with coronary artery disease. Arch Phys Med Rehabil 2004;85:1538-43.
34. Olper L, Cervi P, De Santi F, et al. Validation of the treadmill Six-Minute Walk Test in people following cardiac surgery. Phys Ther 2011;91:566-76.
35. Steiner ME, Ness PM, Assmann SF, et al. Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med 2015;372:1419-29.
36. Chung MK. Cardiac surgery: postoperative arrhythmias. Crit Care Med 2000;28:N136-44.
37. Knotzer H, Dünser MW, Mayr AJ, et al. Postbypass arrhythmias: pathophysiology, prevention, and therapy. Curr Opin Crit Care 2004;10:330-5.
38. Sadikot RT, Rogers JT, Cheng DS, et al. Pleural fluid characteristics of patients with symptomatic pleural effusion after coronary artery bypass graft surgery. Arch Intern Med 2000;160:2665-8.
39. Sockalingam S, Parekh N, Bogoch II, et al. Delirium in the postoperative cardiac patient: a review. J Card Surg 2005;20:560-7.
40. Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood 2012;119:1757-67.
41. Barjas-Castro ML, Angerami RN, Cunha MS, et al. Probable transfusion-transmitted Zika virus in Brazil. Transfusion 2016;56:1684-8.
42. Motta IJ, Spencer BR, Cordeiro da Silva SG, et al. Evidence for transmission of Zika virus by platelet transfusion. N Engl J Med 2016;375:1101-3.
43. Mlakar J, Korva M, Tul N, et al. Zika virus associated with microcephaly. N Engl J Med 2016;374:951-8.
44. Tang H, Hammack C, Ogden SC, et al. Zika virus infects human cortical neural progenitors and attenuates their growth. Cell Stem Cell 2016;18:587-90.
45. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 2016;387:1531-9.
46. Revised recommendations for reducing the risk of Zika virus transmission by blood and blood components. Guidance for industry [Internet]. 2016 [cited 2016 Sep 17]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM518213.pdf.
47. Harboe M. A method for determination of hemoglobin in plasma by near-ultraviolet spectrophotometry. Scand J Clin Lab Invest 1959;11:66-70.
48. Mastronardi C, Perkins H, Derksen P, et al. Evaluation of the BacT/ALERT 3D system for the implementation of in-house quality control sterility testing at Canadian Blood Services. Clin Chem Lab Med 2010;48:1179-87.